GREY:IPHAF - Post by User
Post by
biodelatechon Jun 05, 2008 12:04pm
329 Views
Post# 15149019
From leftfield
From leftfieldhigh dose 247 beat tacro in terms BPAR percentage-wise with slightly better side effects, albeit not in diabetes.
ponder that.
I think it´s a no-brainer that roche will opt in.
voclo is an improvement over tacro.
okay we drawed in the GFR, and the low dose bpar at 11% is not so super, but the rest was a wipe-out.
You just can´t make the case that tacro is the better drug.
Imagine being a patient having the choice between 2 like-effective drugs, with one giving you diabetes with, say,
twice the likelyhood than the other. which drug would you prefer? Stupid question.